YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Shares of Eton Pharmaceuticals ETON have gained about 108% over the past six months compared with the industry's 0.7% growth, fueled by growing investor confidence in the company's strong commercial execution, rapid revenue growth and an e…
Investing.com -- B. Riley analyst Mayank Mamtani has identified top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve's 25 basis point rate hike to 4.00%, its first increase since July 2023. The u…
During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to "cut it off" or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is no…
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. Continue Reading
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months. Continue Reading
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Chief Business Officer-David Krempa Chief Executive Officer-Sean Brynjelsen Chief Commercial Officer-Ipek Trinkaus Chief Financial Officer-Judy…
Eton Pharmaceuticals (NASDAQ: ETON) stock soared 41.9% through 2:15 p.m. ET Friday after beating analyst forecasts for Q2 with a stick. Heading into the report, Wall Street had Eton pegged for a $0.15 per share profit on just $26.9 million…
Key Points Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.10 stocks we like better than Eton Pharmaceuticals › Eton Pharmaceuticals (NASDA…
Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting…
Earnings Call Insights: Eton Pharmaceuticals (ETON) Q2 2026 MANAGEMENT VIEW * CEO Sean Brynjelsen said the company delivered “record revenue, significant margin expansion and important progress across both our commercial portfolio and pipe…
Quant rankings for the upcoming earnings calendar show strength concentrated across information technology, energy, and health care, while weakness is more pronounced in financials and real estate. A total of 735 companies are scheduled to…
Insmed (INSM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $1.7 per share a year ago. These figures are adjusted for non-recurring items. This quarterl…
DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today annou…
Apple upgraded, Brinker initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
(RTTNews) - Even with strong research and disciplined stock selection, an investor may not get every stock pick right. As legendary investor Peter Lynch once said, "In this business, if you're good, you're right six times out of ten. You'r…
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is one of the best oversold growth stocks to invest in now. H.C. Wainwright lifted the price target on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) to $57 from $52 on May 15, reaffirming a Buy rating on…
During stock market uptrends, the 21-day exponential moving average has proved itself to be a strong short-term support for leading stocks. Continue Reading
(RTTNews) - Eton Pharmaceuticals, Inc (ETON) is adding another planned 2026 launch to its rare-disease portfolio as the company secured exclusive U.S. commercialization rights to IMPAVIDO, the only FDA-approved oral therapy for multiple fo…
Image source: The Motley Fool. Date Thursday, May 14, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Sean Brynjelsen Chief Financial Officer — James Gruber Chief Commercial Officer — Ipek Erdogan-Trinkaus Executive Vice P…
Earnings Call Insights: Eton Pharmaceuticals (ETON) Q1 2026 MANAGEMENT VIEW * "The first quarter was another great quarter for Eton. We achieved record product sales delivering 73% year-over-year product revenue growth. We launched 2 new m…
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recu…
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago. These figures are adjusted…
DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today anno…
Eton Pharmaceuticals Inc. (NASDAQ:ETON) is one of the best NASDAQ growth stocks to buy and hold forever. On April 16, Eton Pharmaceuticals announced a succession plan for its Chief Financial Officer, appointing Judith M. Matthews as Execut…
[concept word CFO on metal blocks.close up of metal blocks,Business Concept.3D rendering on red background.] * Shares of Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) fell on Thursday after the company announced that i…
(RTTNews) - Eton Pharmaceuticals Inc. (ETON) on Thursday said it has appointed Judith M. Matthews as Executive Vice President, Accounting and Finance, effective immediately. Matthews will assume the role of Chief Financial Officer on June…
Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high…
On Thursday, Tarsus Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price performance with a 1 (worst)…
The Iran war will be four weeks old come Saturday. With the White House suggesting negotiations are progressing nicely and the Iranians saying America is “negotiating with itself,” this war looks ready to go the distance. That’s never good…
Eton Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Portfolio Evolution Revenue more than doubled in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi. M…
Eton Pharmaceuticals logo Key Points Q4 results: Product revenue rose 83% year‑over‑year to $21.3M with adjusted gross profit of $15.5M (73% margin), GAAP net income of $1.5M and adjusted EBITDA of $6.2M (29%), though operating cash flow s…
Image source: The Motley Fool. DATE Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Sean E. Brynjelsen Chief Financial Officer — James R. Gruber Chief Commercial Officer — Ipek Erwan Need a quote from a…
Image source: The Motley Fool. DATE Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Sean E. BrynjelsenChief Financial Officer — James R. GruberChief Commercial Officer — Ipek Erwan Need a quote from a M…
On February 17, 2026, Opaleye Management Inc. reported selling out its entire stake in Immunome(NASDAQ:IMNM), an estimated $37.30 million trade based on quarterly average pricing. What Happened According to its SEC filing dated February 17…
Opaleye Management Inc. disclosed in a February 17, 2026, SEC filing that it sold 180,000 shares of Liquidia(NASDAQ:LQDA), an estimated $5.12 million trade based on quarterly average pricing. What Happened According to a SEC filing dated F…
(RTTNews) - Eton Pharmaceuticals, Inc. (ETON), a commercial-stage pharmaceutical company, Wednesday announced in-licensing of U.S. commercialisation rights to Hemangeo oral solution from Pierre Fabre Medicament SAS, indicated for the treat…